BXQ-350 possesses tumor agnostic properties and represents a paradigm shift in the fight against cancer. Utilizing a small lysosomal protein known as Saposin C with a lipid, BXQ-350 targets both externalized phosphatidylserine and tumor lysosomes to initiate tumor cell death. In tumor cells and the blood vessels that feed tumors, some of the phosphatidylserine (PS) move to the outside of the cell membrane to help avoid inflammation and the immune response. Under acidic conditions, Saposin C is fusogenic to phosphatidylserine initiating two distinct mechanisms of action to kill cancer cells.

  1. Endocytosis of BXQ-350 leading to lysosomal degradation and necrosis
  2. Catalysis of acid spingomyelinase leading to ceramide elevation & apoptosis

Preclinical Results

  • Identified and targeted tumor cells and tumor vasculature – not healthy cells

  • Tumor agnostic, effective against multiple cancer types

  • Bypassed the Blood Brain Barrier (BBB)
  • Killed tumor cells and not healthy cells
  • Strong safety and tolerability profile
Learn more about bxq-350 clinical trials